

## Regulatory Information

## Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2011

(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Charenton-le-Pont, France (March 3, 2011- 06:00 pm) – As of February 28, 2011, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:

	February 28, 2011
Shares outstanding	211,829,943
Exercisable voting rights	225,551,063
Total voting rights, based on all outstanding shares, including shares stripped of their voting rights*	230,143,441

(*)	) Shares held by	/ the Company	$\prime$ , either in treasur	y or under the	liquidity contract.
-----	------------------	---------------	------------------------------	----------------	---------------------

-----

The world leader in ophthalmic optical products, Essilor International researches, develops, manufactures and markets around the world a wide range of lenses to correct myopia, hyperopia, presbyopia and astigmatism. Its flagship brands are Varilux<sup>®</sup>, Crizal<sup>®</sup>, Essilor<sup>®</sup>, Definity<sup>®</sup> and Xperio<sup>™</sup>.

Based in France, the company reported consolidated revenue of €3.2 billion in 2009, with 34,700 employees and operations in 100 countries.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the CAC 40 index. Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

-----

Investor Relations and Financial Communications

Phone: +33 (0)1 49 77 42 16